Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

21st November, 2026

M/s. BSE Ltd.
Scrip Code: **524816**

M/s. National Stock Exchange of India Ltd
Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, please find enclosed herewith the intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on the U.S. Food and Drug Administration (FDA) inspection at the API manufacturing plant located in Kothur, Hyderabad, India, from 12th November to 20th November, 2026.

This is for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

VENKAT RAMESH CHEKURI
Digitally signed by VENKAT RAMESH CHEKURI
Date: 2026.11.21 11:25:13 +05'30'

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Press Release

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, November 21st, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced conclusion of US FDA Inspection at our Formulation plant located at Kothur, Hyderabad.

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The U.S. Food and Drug Administration (USFDA) conducted an inspection of the Company's Formulation manufacturing facility located in Kothur, Hyderabad, India, from November 12th to November 20th, 2026.

Upon conclusion of the inspection, the Company received seven (7) observations in the Form-483. The Company believes that the observations are procedural in nature and is confident of addressing these observations comprehensively within stipulated timelines.

Please take the above information on record.

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com.

For further information please contact:

Rajeev Menon, Investor Relations

r.menon@natcopharma.co.in/ir@natcopharma.co.in